2021 Q4 Form 10-Q Financial Statement
#000165495421012116 Filed on November 15, 2021
Income Statement
| Concept | 2021 Q4 | 2021 Q3 | 2020 Q3 |
|---|---|---|---|
| Revenue | $250.0K | $159.5K | -$288.6K |
| YoY Change | -252.47% | -155.27% | -396.32% |
| Cost Of Revenue | $29.17K | $53.93K | $25.20K |
| YoY Change | -0.78% | 114.01% | |
| Gross Profit | $220.8K | $105.6K | -$313.8K |
| YoY Change | -214.2% | -133.64% | |
| Gross Profit Margin | 88.33% | 66.18% | |
| Selling, General & Admin | $3.318M | $3.837M | $2.332M |
| YoY Change | -34.24% | 64.55% | 27.24% |
| % of Gross Profit | 1502.41% | 3634.81% | |
| Research & Development | $5.426M | $3.485M | $2.924M |
| YoY Change | 35.27% | 19.18% | -6.51% |
| % of Gross Profit | 2457.28% | 3301.53% | |
| Depreciation & Amortization | $27.59K | $12.56K | $13.44K |
| YoY Change | 165.03% | -6.58% | -26.33% |
| % of Gross Profit | 12.49% | 11.9% | |
| Operating Expenses | $8.773M | $7.375M | $3.657M |
| YoY Change | -3.44% | 101.68% | -26.27% |
| Operating Profit | -$8.451M | -$7.216M | -$3.945M |
| YoY Change | -8.63% | 82.89% | |
| Interest Expense | $2.773K | $5.631K | $7.489K |
| YoY Change | 48.21% | -24.81% | -97.93% |
| % of Operating Profit | |||
| Other Income/Expense, Net | -$235.3K | $103.1K | $4.646K |
| YoY Change | -68.29% | 2119.93% | |
| Pretax Income | -$8.686M | -$7.113M | -$3.941M |
| YoY Change | -13.06% | 80.49% | -12.45% |
| Income Tax | $0.00 | ||
| % Of Pretax Income | |||
| Net Earnings | -$8.686M | -$7.113M | -$3.941M |
| YoY Change | -13.06% | 80.49% | -12.45% |
| Net Earnings / Revenue | -3474.59% | -4459.88% | |
| Basic Earnings Per Share | |||
| Diluted Earnings Per Share | -$36.46K | -$29.86K | -$16.67K |
| COMMON SHARES | |||
| Basic Shares Outstanding | 231.3M shares | ||
| Diluted Shares Outstanding |
Balance Sheet
| Concept | 2021 Q4 | 2021 Q3 | 2020 Q3 |
|---|---|---|---|
| SHORT-TERM ASSETS | |||
| Cash & Short-Term Investments | $47.33M | $53.42M | $86.59M |
| YoY Change | -34.41% | -38.3% | -10.46% |
| Cash & Equivalents | $47.33M | $53.42M | $86.59M |
| Short-Term Investments | |||
| Other Short-Term Assets | $2.380M | $2.947M | $2.360M |
| YoY Change | -6.93% | 24.86% | 294.74% |
| Inventory | $1.079M | $1.108M | $5.793M |
| Prepaid Expenses | |||
| Receivables | $584.0K | $914.0K | $5.044M |
| Other Receivables | $0.00 | $0.00 | $0.00 |
| Total Short-Term Assets | $51.37M | $58.39M | $99.78M |
| YoY Change | -39.91% | -41.48% | 2.45% |
| LONG-TERM ASSETS | |||
| Property, Plant & Equipment | $511.3K | $140.0K | $1.317M |
| YoY Change | -58.43% | -89.37% | 229.93% |
| Goodwill | |||
| YoY Change | |||
| Intangibles | |||
| YoY Change | |||
| Long-Term Investments | |||
| YoY Change | |||
| Other Assets | $56.92K | $56.92K | $56.92K |
| YoY Change | -0.01% | -0.01% | -68.36% |
| Total Long-Term Assets | $1.626M | $1.343M | $1.374M |
| YoY Change | 26.38% | -2.24% | 137.26% |
| TOTAL ASSETS | |||
| Total Short-Term Assets | $51.37M | $58.39M | $99.78M |
| Total Long-Term Assets | $1.626M | $1.343M | $1.374M |
| Total Assets | $52.99M | $59.73M | $101.2M |
| YoY Change | -38.93% | -40.95% | 3.25% |
| SHORT-TERM LIABILITIES | |||
| YoY Change | |||
| Accounts Payable | $160.2K | $762.8K | $971.3K |
| YoY Change | -86.36% | -21.47% | 1579.89% |
| Accrued Expenses | $6.178M | $4.991M | $4.106M |
| YoY Change | 21.98% | 21.56% | 159.96% |
| Deferred Revenue | |||
| YoY Change | |||
| Short-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Long-Term Debt Due | $96.92K | ||
| YoY Change | |||
| Total Short-Term Liabilities | $13.86M | $9.788M | $12.65M |
| YoY Change | 91.24% | -22.64% | 583.78% |
| LONG-TERM LIABILITIES | |||
| Long-Term Debt | $204.9K | $0.00 | $0.00 |
| YoY Change | |||
| Other Long-Term Liabilities | $3.014M | $6.168M | $11.53M |
| YoY Change | -74.23% | -46.51% | |
| Total Long-Term Liabilities | $3.014M | $6.168M | $11.53M |
| YoY Change | -74.23% | -46.51% | |
| TOTAL LIABILITIES | |||
| Total Short-Term Liabilities | $13.86M | $9.788M | $12.65M |
| Total Long-Term Liabilities | $3.014M | $6.168M | $11.53M |
| Total Liabilities | $17.80M | $16.76M | $24.18M |
| YoY Change | -6.04% | -30.68% | 1206.94% |
| SHAREHOLDERS EQUITY | |||
| Retained Earnings | -$367.6M | -$358.9M | |
| YoY Change | |||
| Common Stock | $2.317M | $2.313M | |
| YoY Change | |||
| Preferred Stock | |||
| YoY Change | |||
| Treasury Stock (at cost) | |||
| YoY Change | |||
| Treasury Stock Shares | |||
| Shareholders Equity | $35.20M | $42.97M | $76.98M |
| YoY Change | |||
| Total Liabilities & Shareholders Equity | $52.99M | $59.73M | $101.2M |
| YoY Change | -38.93% | -40.95% | 3.25% |
Cashflow Statement
| Concept | 2021 Q4 | 2021 Q3 | 2020 Q3 |
|---|---|---|---|
| OPERATING ACTIVITIES | |||
| Net Income | -$8.686M | -$7.113M | -$3.941M |
| YoY Change | -13.06% | 80.49% | -12.45% |
| Depreciation, Depletion And Amortization | $27.59K | $12.56K | $13.44K |
| YoY Change | 165.03% | -6.58% | -26.33% |
| Cash From Operating Activities | -$6.289M | -$6.424M | $3.813M |
| YoY Change | -56.39% | -268.47% | -93.05% |
| INVESTING ACTIVITIES | |||
| Capital Expenditures | -$89.10K | -$57.76K | $0.00 |
| YoY Change | -100.0% | ||
| Acquisitions | |||
| YoY Change | |||
| Other Investing Activities | |||
| YoY Change | |||
| Cash From Investing Activities | -$89.10K | -$57.76K | $0.00 |
| YoY Change | -100.0% | ||
| FINANCING ACTIVITIES | |||
| Cash Dividend Paid | |||
| YoY Change | |||
| Common Stock Issuance & Retirement, Net | |||
| YoY Change | |||
| Debt Paid & Issued, Net | |||
| YoY Change | |||
| Cash From Financing Activities | 282.3K | -$202.4K | -$77.77K |
| YoY Change | -2606.66% | 160.21% | -95.1% |
| NET CHANGE | |||
| Cash From Operating Activities | -6.289M | -$6.424M | $3.813M |
| Cash From Investing Activities | -89.10K | -$57.76K | $0.00 |
| Cash From Financing Activities | 282.3K | -$202.4K | -$77.77K |
| Net Change In Cash | -6.096M | -$6.684M | $3.735M |
| YoY Change | -57.76% | -278.94% | -92.98% |
| FREE CASH FLOW | |||
| Cash From Operating Activities | -$6.289M | -$6.424M | $3.813M |
| Capital Expenditures | -$89.10K | -$57.76K | $0.00 |
| Free Cash Flow | -$6.200M | -$6.366M | $3.813M |
| YoY Change | -57.01% | -266.95% | -93.05% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2021Q4 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
231345273 | shares |
| CY2021Q3 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
53421179 | USD |
| CY2021Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
60104919 | USD |
| CY2021Q3 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
762817 | USD |
| CY2021Q2 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
640650 | USD |
| CY2021Q3 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
4991164 | USD |
| CY2021Q2 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
5797378 | USD |
| CY2021Q3 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
353925 | USD |
| CY2021Q2 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
351853 | USD |
| CY2021Q3 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
6167603 | USD |
| CY2021Q2 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
6232907 | USD |
| CY2021Q3 | us-gaap |
Liabilities
Liabilities
|
16764201 | USD |
| CY2021Q2 | us-gaap |
Liabilities
Liabilities
|
17645215 | USD |
| CY2021Q3 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.01 | |
| CY2021Q3 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
10000000 | shares |
| CY2021Q3 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
40 | USD |
| CY2021Q2 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
40 | USD |
| CY2021Q3 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.01 | |
| CY2021Q3 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
300000000 | shares |
| CY2021Q3 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
231301673 | shares |
| CY2021Q3 | us-gaap |
Common Stock Value
CommonStockValue
|
2313017 | USD |
| CY2021Q2 | us-gaap |
Common Stock Value
CommonStockValue
|
2300497 | USD |
| CY2021Q3 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
399564086 | USD |
| CY2021Q2 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
399146232 | USD |
| CY2021Q3 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-358908016 | USD |
| CY2021Q2 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-351795397 | USD |
| CY2021Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
42969127 | USD |
| CY2021Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
49651372 | USD |
| CY2021Q3 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
59733328 | USD |
| CY2021Q2 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
67296587 | USD |
| CY2021Q3 | ptn |
Product Revenue Net
ProductRevenueNet
|
159482 | USD |
| CY2020Q3 | ptn |
Product Revenue Net
ProductRevenueNet
|
-288560 | USD |
| CY2021Q3 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
3484764 | USD |
| CY2020Q3 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
2923851 | USD |
| CY2021Q3 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
3836542 | USD |
| CY2020Q3 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
2331606 | USD |
| CY2021Q3 | us-gaap |
Gain Loss On Contract Termination
GainLossOnContractTermination
|
0 | USD |
| CY2021Q3 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-7215757 | USD |
| CY2021Q3 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
1410 | USD |
| CY2020Q3 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
12135 | USD |
| CY2021Q3 | us-gaap |
Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
|
107359 | USD |
| CY2020Q3 | us-gaap |
Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
|
0 | USD |
| CY2021Q3 | us-gaap |
Interest Expense
InterestExpense
|
5631 | USD |
| CY2020Q3 | us-gaap |
Interest Expense
InterestExpense
|
7489 | USD |
| CY2021Q3 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
103138 | USD |
| CY2020Q3 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
4646 | USD |
| CY2021Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-7112619 | USD |
| CY2020Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-3940776 | USD |
| CY2021Q3 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.03 | |
| CY2020Q3 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.02 | |
| CY2021Q3 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
238233063 | shares |
| CY2020Q3 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
236345862 | shares |
| CY2021Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
49651372 | USD |
| CY2021Q3 | us-gaap |
Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
|
632727 | USD |
| CY2021Q3 | ptn |
Taxes Withheld Related To Restricted Stock Units
TaxesWithheldRelatedToRestrictedStockUnits
|
-202353 | USD |
| CY2021Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-7112619 | USD |
| CY2021Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
42969127 | USD |
| CY2020Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
80172849 | USD |
| CY2020Q3 | us-gaap |
Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
|
821174 | USD |
| CY2020Q3 | ptn |
Taxes Withheld Related To Restricted Stock Units
TaxesWithheldRelatedToRestrictedStockUnits
|
-77766 | USD |
| CY2020Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-3940776 | USD |
| CY2020Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
76975481 | USD |
| CY2021Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-7112619 | USD |
| CY2020Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-3940776 | USD |
| CY2021Q3 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
12559 | USD |
| CY2020Q3 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
13444 | USD |
| CY2021Q3 | ptn |
Gain On Termination Agreement
GainOnTerminationAgreement
|
0 | USD |
| CY2020Q3 | ptn |
Gain On Termination Agreement
GainOnTerminationAgreement
|
10376205 | USD |
| CY2021Q3 | us-gaap |
Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
|
91481 | USD |
| CY2020Q3 | us-gaap |
Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
|
75722 | USD |
| CY2021Q3 | ptn |
Unrealized Foreign Currency Transaction Gain
UnrealizedForeignCurrencyTransactionGain
|
-107359 | USD |
| CY2020Q3 | ptn |
Unrealized Foreign Currency Transaction Gain
UnrealizedForeignCurrencyTransactionGain
|
0 | USD |
| CY2021Q3 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
632727 | USD |
| CY2020Q3 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
821174 | USD |
| CY2021Q3 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
666428 | USD |
| CY2020Q3 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
-744372 | USD |
| CY2021Q3 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
112882 | USD |
| CY2020Q3 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-1621785 | USD |
| CY2021Q3 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
53933 | USD |
| CY2020Q3 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
25200 | USD |
| CY2021Q3 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
122167 | USD |
| CY2020Q3 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
255636 | USD |
| CY2021Q3 | us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
-806214 | USD |
| CY2020Q3 | us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
-1375415 | USD |
| CY2021Q3 | ptn |
Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
|
-89608 | USD |
| CY2020Q3 | ptn |
Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
|
-72082 | USD |
| CY2021Q3 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-6423623 | USD |
| CY2020Q3 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
3812951 | USD |
| CY2020Q3 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
0 | USD |
| CY2021Q3 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-57764 | USD |
| CY2020Q3 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
0 | USD |
| CY2021Q3 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
-202353 | USD |
| CY2021Q3 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
-6683740 | USD |
| CY2020Q3 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
3735185 | USD |
| CY2021Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
60104919 | USD |
| CY2020Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
82852270 | USD |
| CY2021Q3 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
53421179 | USD |
| CY2020Q3 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
86587455 | USD |
| CY2021Q3 | us-gaap |
Interest Paid Net
InterestPaidNet
|
5631 | USD |
| CY2021Q3 | us-gaap |
Nature Of Operations
NatureOfOperations
|
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><em>Nature of Business </em>- Palatin Technologies, Inc. (“Palatin” or the “Company”) is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. The Company’s product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><em>Melanocortin Receptor System.</em> The melanocortin receptor (“MCr”) system has effects on food intake, metabolism, sexual function, inflammation, and immune system responses. There are five melanocortin receptors, MC1r through MC5r. Modulation of these receptors, through use of receptor-specific agonists, which activate receptor function, or receptor-specific antagonists, which block receptor function, can have significant pharmacological effects. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The Company’s lead product, Vyleesi®, was approved by the U.S. Food and Drug Administration (“FDA”) in June 2019 and was being marketed in North America by AMAG Pharmaceuticals, Inc. (“AMAG”) for the treatment of hypoactive sexual desire disorder (“HSDD”) in premenopausal women pursuant to a license agreement between them for Vyleesi for North America, which was entered into on January 8, 2017 (the “AMAG License Agreement”). As disclosed in Note 5, the AMAG License Agreement was terminated effective July 24, 2020, and the Company is now marketing Vyleesi in North America. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The Company’s new product development activities focus primarily on MC1r agonists, with potential to treat inflammatory and autoimmune diseases such as dry eye disease, which is also known as keratoconjunctivitis sicca, uveitis, diabetic retinopathy, and inflammatory bowel disease. The Company believes that the MC1r agonist peptides in development have broad anti-inflammatory effects and appear to utilize mechanisms engaged by the endogenous melanocortin system in regulation of the immune system and resolution of inflammatory responses. The Company is also developing peptides that are active at more than one melanocortin receptor, and MC4r peptide and small molecule agonists with potential utility in obesity and metabolic-related disorders, including rare disease and orphan indications.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><em>Natriuretic Peptide Receptor System</em>. The natriuretic peptide receptor (“NPR”) system regulates cardiovascular functions and tissue homeostasis, and therapeutic agents modulating this system have potential to treat cardiovascular and fibrotic diseases. The Company has designed and is developing potential NPR candidate drugs selective for one or more different natriuretic peptide receptors, including natriuretic peptide receptor-A (“NPR-A”), natriuretic peptide receptor B (“NPR-B”), and natriuretic peptide receptor C (“NPR-C”).</p> | |
| CY2021Q3 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-358908016 | USD |
| CY2021Q3 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
53421179 | USD |
| CY2021Q3 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
9787758 | USD |
| CY2021Q3 | us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><em>Concentrations –</em> Concentrations in the Company’s assets and operations subject it to certain related risks. Financial instruments that subject the Company to concentrations of credit risk primarily consist of cash, cash equivalents, and accounts receivable. The Company’s cash and cash equivalents are primarily invested in one money market account sponsored by a large financial institution. </p> | |
| CY2021Q3 | us-gaap |
Basis Of Accounting
BasisOfAccounting
|
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong>(2) BASIS OF PRESENTATION</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q. Accordingly, they do not include all of the information and footnote disclosures required to be presented for complete financial statements. In the opinion of management, these consolidated financial statements contain all adjustments (consisting of normal recurring adjustments) considered necessary for fair presentation. The results of operations for the three months ended September 30, 2021 may not necessarily be indicative of the results of operations expected for the full year.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The accompanying unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended June 30, 2021, filed with the Securities and Exchange Commission (“SEC”), which includes consolidated financial statements as of June 30, 2021 and 2020 and for the fiscal years then ended.</p> | |
| CY2021Q3 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><em>Use of Estimates</em> – The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p> | |
| CY2021Q3 | us-gaap |
Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
|
52554495 | USD |
| CY2021Q2 | us-gaap |
Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
|
59730428 | USD |
| CY2021Q3 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
2516525 | USD |
| CY2021Q2 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
2503966 | USD |
| CY2021Q3 | ptn |
Accrued Expenses
AccruedExpenses
|
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><em>Accrued Expenses –</em> Third parties perform a significant portion of the Company’s development activities. The Company reviews the activities performed under all contracts each quarter and accrues expenses and the amount of any reimbursement to be received from its collaborators based upon the estimated amount of work completed considering milestones achieved. Estimating the value or stage of completion of certain services requires judgment based on available information. If the Company does not identify services performed for it but not billed by the service-provider, or if it underestimates or overestimates the value of services performed as of a given date, reported expenses will be understated or overstated.</p> | |
| CY2021Q3 | us-gaap |
Related Party Transaction Purchases From Related Party
RelatedPartyTransactionPurchasesFromRelatedParty
|
18194000 | USD |
| CY2021Q3 | us-gaap |
Line Of Credit Facility Increase Accrued Interest
LineOfCreditFacilityIncreaseAccruedInterest
|
2300000 | USD |
| CY2020Q3 | us-gaap |
Gain Loss On Contract Termination
GainLossOnContractTermination
|
1623795 | USD |
| CY2021Q3 | us-gaap |
Loss On Contract Termination
LossOnContractTermination
|
4407987 | USD |
| CY2021Q2 | ptn |
Net Loss
NetLoss
|
2784192 | USD |
| CY2021Q3 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
32931560 | shares |
| CY2020Q3 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
38526609 | shares |
| CY2021Q3 | us-gaap |
Weighted Average Number Of Shares Restricted Stock
WeightedAverageNumberOfSharesRestrictedStock
|
6734125 | shares |
| CY2020Q3 | us-gaap |
Weighted Average Number Of Shares Restricted Stock
WeightedAverageNumberOfSharesRestrictedStock
|
6444353 | shares |
| CY2021Q3 | ptn |
Agreement With Amag
AgreementWithAMAG
|
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong>(5) AGREEMENTS WITH AMAG </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">On January 8, 2017, the Company entered into the AMAG License Agreement pursuant to which the Company granted AMAG (i) an exclusive license in all countries of North America (the “Territory”), with the right to grant sub-licenses, to research, develop, and commercialize products containing Vyleesi (each a “Product”, and collectively, “Products”), (ii) a non-exclusive license in the Territory, with the right to grant sub-licenses, to manufacture the Products, and (iii) a non-exclusive license in all countries outside the Territory, with the right to grant sub-licenses, to research, develop, and manufacture (but not commercialize) the Products.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Following the satisfaction of certain conditions to closing, the AMAG License Agreement became effective on February 2, 2017. Under the AMAG License Agreement, in addition to certain initial and milestone payments, AMAG reimbursed the Company for certain reasonable, documented, direct out-of-pocket expenses incurred by the Company following February 2, 2017, in connection with development and regulatory activities necessary to file a New Drug Application (“NDA”) for Vyleesi for HSDD in the United States. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">On June 4, 2018, the FDA accepted the Vyleesi NDA for filing and on June 21, 2019, the FDA granted approval of Vyleesi for use in the United States. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Effective July 24, 2020, the Company entered into a termination agreement (the “Termination Agreement”) with AMAG terminating the AMAG License Agreement. Under the terms of the Termination Agreement, the Company regained all development and commercialization rights for Vyleesi in the Territory. AMAG made a $12,000,000 payment to the Company at closing of the Termination Agreement and a $4,300,000 payment to the Company on March 31, 2021. The Company initially recorded a liability related to estimated losses on inventory purchase commitments of $18,194,000 as well as accrued expenses for an inventory production run obligation assumed of $2,300,000. The Company assumed all Vyleesi manufacturing agreements, and AMAG transferred information, data, and assets related exclusively to Vyleesi to the Company, including existing inventory and prepaid expenses with an estimated fair value of $5,817,795 as of the date of the Termination Agreement. As a result, the Company initially recorded a net gain for the Termination Agreement of $1,623,795 during the three months ended September 30, 2020. During the three months ended June 30, 2021, the Company reassessed the estimated net realizable value of the inventory, prepaid expenses and losses on the inventory purchase commitments resulting in recording of a loss on the Termination Agreement of $4,407,987 for the three months ended June 30, 2021 and a total loss on the Termination Agreement for the year ended June 30, 2021 of $2,784,192. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Under the Termination Agreement, AMAG provided certain transitional services to the Company for a period to ensure continued patient access to Vyleesi during the transition back to the Company. The Company reimbursed AMAG for the agreed upon costs of the transition services.</p> | |
| CY2020Q3 | ptn |
Contract Termination Agreement Payments
ContractTerminationAgreementPayments
|
12000000 | USD |
| CY2021Q1 | ptn |
Contract Termination Agreement Payments
ContractTerminationAgreementPayments
|
4300000 | USD |
| CY2020Q3 | ptn |
Terminationofcontract
Terminationofcontract
|
-6000000 | EUR |
| CY2021Q3 | ptn |
Agreement With Fosun
AgreementWithFosun
|
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong>(7) AGREEMENT WITH FOSUN</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">On September 6, 2017, the Company entered into a license agreement with Shanghai Fosun Pharmaceutical Development Co. Ltd. (“Fosun”) for exclusive rights to commercialize Vyleesi in China (the “Fosun License Agreement”). Under the terms of the agreement, the Company received $4,500,000 in October 2017, which consisted of an upfront payment of $5,000,000 less $500,000 that was withheld in accordance with tax withholding requirements in China and recorded as an expense. The Company will receive a $7,500,000 milestone payment when regulatory approval in China is obtained, provided that a commercial supply agreement for Vyleesi has been entered into. Palatin has the potential to receive up to $92,500,000 in additional sales related milestone payments and high single-digit to low double-digit royalties on net sales in the licensed territory. All development, regulatory, sales, marketing, and commercial activities and associated costs in the licensed territory will be the sole responsibility of Fosun.</p> | |
| CY2017Q4 | us-gaap |
Increase Decrease In Deferred Revenue And Customer Advances And Deposits
IncreaseDecreaseInDeferredRevenueAndCustomerAdvancesAndDeposits
|
4500000 | USD |
| CY2017Q4 | us-gaap |
Payments For Restructuring
PaymentsForRestructuring
|
5000000 | USD |
| CY2017Q4 | ptn |
Taxexpenses
taxexpenses
|
500000 | USD |
| CY2017Q4 | us-gaap |
Payments To Acquire Receivables
PaymentsToAcquireReceivables
|
7500000 | USD |
| CY2017Q4 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
|
92500000 | USD |
| CY2017Q4 | us-gaap |
Officers Compensation
OfficersCompensation
|
417500 | USD |
| CY2017Q4 | us-gaap |
Payments For Restructuring
PaymentsForRestructuring
|
500000 | USD |
| CY2017Q4 | ptn |
Taxexpenses
taxexpenses
|
82500 | USD |
| CY2017Q4 | us-gaap |
Payments To Acquire Receivables
PaymentsToAcquireReceivables
|
3000000 | USD |
| CY2021Q3 | ptn |
Prepaid Clinical Study Costs
PrepaidClinicalStudyCosts
|
295073 | USD |
| CY2021Q2 | ptn |
Prepaid Clinical Study Costs
PrepaidClinicalStudyCosts
|
454750 | USD |
| CY2021Q3 | ptn |
Prepaid Insurance Premiums
PrepaidInsurancePremiums
|
332713 | USD |
| CY2021Q2 | ptn |
Prepaid Insurance Premiums
PrepaidInsurancePremiums
|
259468 | USD |
| CY2021Q3 | ptn |
Vyleesi Contractual Advances
VyleesiContractualAdvances
|
1200000 | USD |
| CY2021Q2 | ptn |
Vyleesi Contractual Advances
VyleesiContractualAdvances
|
1200000 | USD |
| CY2021Q3 | us-gaap |
Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
|
1119011 | USD |
| CY2021Q2 | us-gaap |
Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
|
1145461 | USD |
| CY2021Q3 | us-gaap |
Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
|
2946797 | USD |
| CY2021Q2 | us-gaap |
Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
|
3059679 | USD |
| CY2021Q3 | us-gaap |
Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
|
52554495 | USD |
| CY2021Q2 | us-gaap |
Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
|
59730428 | USD |
| CY2021Q3 | ptn |
Clinical Study Costs
ClinicalStudyCosts
|
57960 | USD |
| CY2021Q2 | ptn |
Clinical Study Costs
ClinicalStudyCosts
|
778705 | USD |
| CY2021Q3 | ptn |
Other Research Related Expenses
OtherResearchRelatedExpenses
|
627268 | USD |
| CY2021Q2 | ptn |
Other Research Related Expenses
OtherResearchRelatedExpenses
|
569370 | USD |
| CY2021Q3 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
25000 | USD |
| CY2021Q2 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
84094 | USD |
| CY2021Q3 | ptn |
Accrued Expenses Inventory Purchases
AccruedExpensesInventoryPurchases
|
1917633 | USD |
| CY2021Q2 | ptn |
Accrued Expenses Inventory Purchases
AccruedExpensesInventoryPurchases
|
2340000 | USD |
| CY2021Q3 | ptn |
Accrued Selling Expenses
AccruedSellingExpenses
|
2153557 | USD |
| CY2021Q2 | ptn |
Accrued Selling Expenses
AccruedSellingExpenses
|
1839724 | USD |
| CY2021Q3 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
209746 | USD |
| CY2021Q2 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
185485 | USD |
| CY2021Q3 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
4991164 | USD |
| CY2021Q2 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
5797378 | USD |
| CY2021Q3 | us-gaap |
Advances On Inventory Purchases
AdvancesOnInventoryPurchases
|
10809004 | USD |
| CY2021Q3 | us-gaap |
Other Liabilities Current
OtherLiabilitiesCurrent
|
3679852 | USD |
| CY2021Q3 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
6167603 | USD |
| CY2021Q2 | us-gaap |
Other Liabilities Current
OtherLiabilitiesCurrent
|
3721907 | USD |
| CY2021Q2 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
6232907 | USD |
| CY2021Q3 | us-gaap |
Stock Option Plan Expense
StockOptionPlanExpense
|
398812 | USD |
| CY2020Q3 | us-gaap |
Stock Option Plan Expense
StockOptionPlanExpense
|
481822 | USD |
| CY2021Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
21882500 | shares |
| CY2021Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
0.72 | |
| CY2021Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
|
P7Y2M12D | |
| CY2021Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
1034273 | USD |
| CY2021Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
60150 | shares |
| CY2021Q3 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
0.46 | |
| CY2021Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
|
118152 | shares |
| CY2021Q3 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
|
0.70 | |
| CY2021Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
21824498 | shares |
| CY2021Q3 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P6Y10M24D | |
| CY2021Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
186886 | USD |
| CY2021Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
|
0.75 | |
| CY2021Q3 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
|
P5Y9M18D | |
| CY2021Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
|
186886 | USD |
| CY2021Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
|
8358726 | shares |
| CY2021Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
|
0.68 | |
| CY2021Q3 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
|
P8Y9M18D | |
| CY2021Q3 | ptn |
Unvested Performance Based Restricted Stock
UnvestedPerformanceBasedRestrictedStock
|
1605573 | USD |
| CY2020Q3 | ptn |
Unvested Performance Based Restricted Stock
UnvestedPerformanceBasedRestrictedStock
|
332785 | USD |
| CY2021Q3 | us-gaap |
Restricted Stock Expense
RestrictedStockExpense
|
233915 | USD |
| CY2020Q3 | us-gaap |
Restricted Stock Expense
RestrictedStockExpense
|
339352 | USD |
| CY2021Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
|
14840762 | shares |
| CY2021Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures
|
81117 | shares |
| CY2021Q3 | ptn |
Restricted Stock Vested In Period
RestrictedStockVestedInPeriod
|
-1624158 | shares |
| CY2021Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
|
13135487 | shares |
| CY2021Q3 | ptn |
Vested Shares Not Issued
VestedSharesNotIssued
|
6734125 | USD |
| CY2021Q2 | ptn |
Performance Based Restricted Stock
PerformanceBasedRestrictedStock
|
450000 | shares |
| CY2021Q2 | us-gaap |
Shares Issued Price Per Share
SharesIssuedPricePerShare
|
2.00 | |
| CY2021Q3 | ptn |
Vesting Of Restricted Share
VestingOfRestrictedShare
|
372176 | shares |
| CY2020Q3 | ptn |
Vesting Of Restricted Share
VestingOfRestrictedShare
|
146095 | shares |
| CY2021Q3 | ptn |
Aggregate Value
AggregateValue
|
202353 | USD |
| CY2020Q3 | ptn |
Aggregate Value
AggregateValue
|
77766 | USD |
